Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

Recursion chief executive Chris Gibson said that combining the two ... the company secured a $674 million discovery alliance with German group Merck KGaA covering up to three small-molecule ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit ...

This study shows that RNA decay rather than the presence of premature termination codons triggers a TA-like response.

Plus: JetBlue CEO eyes more growth in Boston; AG Andrea Campbell offers fiery words about Trump; Charles River chamber offers ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

In CQV Co. Ltd. v. Merck Patent GmbH, the Federal Circuit addressed (1) the interaction of indemnification agreements with ...